Jacques Genest - Concepedia

Author

Jacques Genest

Montreal Clinical Research Institute ORCID

Also Known As

Genest, J, J GENEST, J Genest, J J Genest, J Jr Genest, J. GENEST, J. GENEST,, J. Genest, J. Genest Jr., J. J. Genest

972

Publications

70.2K

Citations

105

H-Index

291

Concepts

All Affiliations

Montreal Clinical Research Institute McGill University McGill University Health Centre Université de Montréal Royal Victoria Hospital

About

Jacques Genest is an author at Montreal Clinical Research Institute specializing in medicine, cardiovascular disease, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	74	304	28.1K
2	Health Sciences	26	45	3.3K
3	Engineering	3	3	140
4	Arts	1	1	80
5	Education	1	1	11

Jacques Genest

438

Publications

53.9K

Citations

H-Index

Page 1

	Year	Citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Paul M. Ridker, Tom Thurén, Jean MacFadyen, New England Journal of Medicine	2017	8.7K
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2008	6.5K
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Obstetrical & Gynecological Survey Vascular DiseaseElevated C-reactive ProteinUnstable AnginaHyperlipidemiaPharmacotherapy	2009	3.7K
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency Angela Brooks‐Wilson, Michel Marcil, Susanne M. Clee, Nature Genetics Mendelian DisorderDisease MechanismGenetic DisorderMedicineGenetics	1999	1.7K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Paul M. Ridker, Jean MacFadyen, Tom Thurén, The Lancet InflammationAllergyLung InflammationMedicineMetronomic Therapy	2017	1.3K
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, The Lancet Jupiter TrialCardiovascular DiseaseHyperlipidemiaLdl CholesterolDyslipidemia	2009	1K
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Paul M. Ridker, Jean MacFadyen, Peter Libby, The Lancet Cardiovascular ToxicityC-reactive Protein ReductionCardiovascular DiseaseCardiovascular PharmacologyEvent Reduction	2017	847
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults Glen J. Pearson, George Thanassoulis, Todd J. Anderson, Canadian Journal of Cardiology EpidemiologyCardiovascular EpidemiologyHealth PolicyCardiometabolic RiskCardiovascular Disease	2021	800
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism Robert J. Glynn, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2009	741
Familial lipoprotein disorders in patients with premature coronary artery disease. Jacques Genest, Sarah Martin-Munley, Judith McNamara, Circulation	1992	601

Page 1